The MCL1 inhibitor S63845 is tolerable and effective in diverse cancer models

被引：789

作者：

Kotschy, Andras ^{[1
]}

Szlavik, Zoltan ^{[1
]}

Murray, James ^{[2
]}

Davidson, James ^{[2
]}

Maragno, Ana Leticia ^{[3
]}

Le Toumelin-Braizat, Gaetane ^{[3
]}

Chanrion, Maia ^{[3
]}

Kelly, Gemma L. ^{[4
,5
]}

Gong, Jia-Nan ^{[4
,5
]}

Moujalled, Donia M. ^{[6
]}

Bruno, Alain ^{[3
]}

Sekei, Marton C. ^{[1
]}

Paczal, Attila ^{[1
]}

Szabo, Zoltan B. ^{[1
]}

Sipos, Szabolcs ^{[1
]}

Radics, Gabor ^{[1
]}

Proszenyak, Agnes ^{[1
]}

Balint, Balazs ^{[1
]}

Ondi, Levente ^{[1
]}

Blasko, Gabor ^{[1
]}

Robertson, Alan ^{[2
]}

Surgenor, Allan ^{[2
]}

Dokurno, Pawel ^{[2
]}

Chen, Ijen ^{[2
]}

Matassova, Natalia ^{[2
]}

Smith, Julia ^{[2
]}

Pedder, Christopher ^{[2
]}

Graham, Christopher ^{[2
]}

Studeny, Aurelie ^{[3
]}

Lysiak-Auvity, Gaelle ^{[3
]}

Girard, Anne-Marie ^{[3
]}

Grave, Fabienne ^{[3
]}

Segal, David ^{[4
,5
]}

Riffkin, Chris D. ^{[4
,5
]}

Pomilio, Giovanna ^{[6
]}

Galbraith, Laura C. A. ^{[4
,5
]}

Aubrey, Brandon J. ^{[4
,5
,7
]}

Brennan, Margs S. ^{[4
,5
]}

Herold, Marco J. ^{[4
,5
]}

Chang, Catherine ^{[4
,5
]}

Guasconi, Ghislaine ^{[3
]}

Auquil, Nicolas C. ^{[3
]}

Melchiore, Fabien ^{[8
]}

Guigal-Stephan, Nolwen ^{[8
]}

Lockhart, Brian ^{[8
]}

Colland, Frederic ^{[3
]}

Hickman, John A. ^{[3
]}

Roberts, Andrew W. ^{[4
,5
,9
]}

Huang, David C. S. ^{[4
,5
]}

Wei, Andrew H. ^{[6
,10
]}

机构：

[1] Servier Res Inst Med Chem, H-1031 Budapest, Hungary

[2] Vernalis R&D Ltd, Cambridge CB21 6GB, England

[3] Inst Rech Servier Oncol, R&D Unit, F-78290 Croissy Sur Seine, France

[4] Walter & Eliza Hall Inst Med Res, Melbourne, Vic 3052, Australia

[5] Univ Melbourne, Dept Med Biol, Melbourne, Vic 3010, Australia

[6] Monash Univ, Australian Ctr Blood Dis, Melbourne, Vic 3004, Australia

[7] Royal Melbourne Hosp, Victorian Comprehens Canc Ctr, Dept Clin Haematol & Bone Marrow Transplantat, Melbourne, Vic 3050, Australia

[8] Inst Rech Servier, Biomarker Res Div, F-78290 Croissy Sur Seine, France

[9] Univ Melbourne, Fac Med, Melbourne, Vic 3010, Australia

[10] Alfred Hosp, Dept Clin Haematol, Melbourne, Vic 3004, Australia

[11] Univ Melbourne, Dept Pharmacol & Pharmaceut, Melbourne, Vic 3010, Australia

来源：

NATURE | 2016年 / 538卷 / 7626期

基金：

英国医学研究理事会;

关键词：

ANTI-APOPTOTIC MCL-1; BCL-XL; MULTIPLE-MYELOMA; HIGH-AFFINITY; TUMOR-CELLS; SURVIVAL; PROTEIN; COMBINATION; DEPENDENCY; NAVITOCLAX;

D O I：

10.1038/nature19830

中图分类号：

O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];

学科分类号：

07 ; 0710 ; 09 ;

摘要：

Avoidance of apoptosis is critical for the development and sustained growth of tumours. The pro-survival protein myeloid cell leukemia 1 (MCL1) is overexpressed in many cancers, but the development of small molecules targeting this protein that are amenable for clinical testing has been challenging. Here we describe S63845, a small molecule that specifically binds with high affinity to the BH3-binding groove of MCL1. Our mechanistic studies demonstrate that S63845 potently kills MCL1-dependent cancer cells, including multiple myeloma, leukaemia and lymphoma cells, by activating the BAX/BAK-dependent mitochondrial apoptotic pathway. In vivo, S63845 shows potent anti-tumour activity with an acceptable safety margin as a single agent in several cancers. Moreover, MCL1 inhibition, either alone or in combination with other anti-cancer drugs, proved effective against several solid cancer-derived cell lines. These results point towards MCL1 as a target for the treatment of a wide range of tumours.

引用

页码：477 / +

页数：20

共 50 条

[1] The MCL1 inhibitor S63845 is tolerable and effective in diverse cancer models
András Kotschy
Zoltán Szlavik
James Murray
James Davidson
Ana Leticia Maragno
Gaëtane Le Toumelin-Braizat
Maïa Chanrion
Gemma L. Kelly
Jia-Nan Gong
Donia M. Moujalled
Alain Bruno
Márton Csekei
Attila Paczal
Zoltán B. Szabo
Szabolcs Sipos
Gábor Radics
Agnes Proszenyak
Balázs Balint
Levente Ondi
Gábor Blasko
Alan Robertson
Allan Surgenor
Pawel Dokurno
Ijen Chen
Natalia Matassova
Julia Smith
Christopher Pedder
Christopher Graham
Aurélie Studeny
Gaëlle Lysiak-Auvity
Anne-Marie Girard
Fabienne Gravé
David Segal
Chris D. Riffkin
Giovanna Pomilio
Laura C. A. Galbraith
Brandon J. Aubrey
Margs S. Brennan
Marco J. Herold
Catherine Chang
Ghislaine Guasconi
Nicolas Cauquil
Fabien Melchiore
Nolwen Guigal-Stephan
Brian Lockhart
Frédéric Colland
John A. Hickman
Andrew W. Roberts
David C. S. Huang
Andrew H. Wei
Nature, 2016, 538 : 477 - 482
[2] Efficacy of MCL1 inhibitor S63845 in small cell lung cancer
Yasuda, Yuto
Ozasa, Hiroaki
Tsuji, Takahiro
Nomizo, Takashi
Yamamoto, Tomoko
Ajimizu, Hitomi
Yoshida, Hironori
Sakamori, Yuichi
Hirai, Toyohiro
Kim, Young Hak
CANCER SCIENCE, 2018, 109 : 409 - 409
[3] Efficacy of MCL1 inhibitor S63845 in small cell lung cancer
Yasuda, Yuto
Ozasa, Hiroaki
Tsuji, Takahiro
Nomizo, Takashi
Funazo, Tomoko
Yoshida, Hironori
Sakamori, Yuichi
Hirai, Toyohiro
Kim, Young Hak
CANCER RESEARCH, 2018, 78 (13)
[4] Venetoclax, bortezomib and S63845, an MCL1 inhibitor, in multiple myeloma
Wong, Kwan Yeung
Chim, Chor Sang
JOURNAL OF PHARMACY AND PHARMACOLOGY, 2020, 72 (05) : 728 - 737
[5] In vitro and in vivo efficacy of MCL1 inhibitor S63845 in small cell lung cancer
Yasuda, Yuto
Ozasa, Hiroaki
Tsuji, Takahiro
Nomizo, Takashi
Yamamoto, Tomoko
Ajimizu, Hitomi
Yoshida, Hironori
Sakamori, Yuichi
Hirai, Toyohiro
Kim, Young Hak
CANCER RESEARCH, 2019, 79 (13)
[6] Constitutive BAK/MCL1 complexes predict paclitaxel and S63845 sensitivity of ovarian cancer
Liu, Dongyan
Hou, Xiaonan
Wu, Wangyu
Zafagnin, Valentina
Li, Yunjian
Correia, Cristina
Zhao, Zhiyang
Zhao, Chenggang
Liu, Zhirong
Zhang, Tao
Fang, Zhiyou
Wang, Hongzhi
Xu, Chao
Weroha, Saravut J.
Kaufmann, Scott H.
Dai, Haiming
CELL DEATH & DISEASE, 2021, 12 (08)
[7] Constitutive BAK/MCL1 complexes predict paclitaxel and S63845 sensitivity of ovarian cancer
Dongyan Liu
Xiaonan Hou
Wangyu Wu
Valentina Zanfagnin
Yunjian Li
Cristina Correia
Zhiyang Zhao
Chenggang Zhao
Zhirong Liu
Tao Zhang
Zhiyou Fang
Hongzhi Wang
Chao Xu
Saravut J. Weroha
Scott H. Kaufmann
Haiming Dai
Cell Death & Disease, 12
[8] MCL1 Small Molecule Inhibitor S63845 Synergizes with Cisplatin in Basal-like Triple Negative Breast Cancer
Acton, Alexus
Placzek, William
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2023, 385
[9] Correction: Constitutive BAK/MCL1 complexes predict paclitaxel and S63845 sensitivity of ovarian cancer
Dongyan Liu
Xiaonan Hou
Wangyu Wu
Valentina Zafagnin
Yunjian Li
Cristina Correia
Zhiyang Zhao
Chenggang Zhao
Zhirong Liu
Tao Zhang
Zhiyou Fang
Hongzhi Wang
Chao Xu
Saravut J. Weroha
Scott H. Kaufmann
Haiming Dai
Cell Death & Disease, 12
[10] MCL1 inhibitor S63845 delivered by follicle-stimulating hormone modified liposome potentiates carboplatin efficacy in ovarian cancer
Zhang, Yanan
Wang, Qingzhen
Li, Wenxin
Li, Xin
Li, Yuqing
Liu, Zhihua
Zhou, Huige
Luo, Aiping
Chen, Chunying
Li, Bin
NANO TODAY, 2024, 59

← 1 2 3 4 5 →